Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Poster and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 - AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN - HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Investors & Media
  • Contact
    Top Links
    • Investors & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Poster and Presentations
      • Scientific Manuscripts
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 - AML
      • KOMET-007 - AML
      • KOMET-008 - AML
      • Tipifarnib Clinical Trials
      • KURRENT-HN - HNSCC
      • KO-2806 Clinical Trials
      • FIT-001 - Solid Tumors
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Investors & Media
    • Contact
    • MenuMenu

    Investors & Media

    Investor News and Information

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Corporate Profile

    We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small-molecule product candidates that target cancer signaling pathways, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We intend to advance our product candidates through a combination of internal development and strategic partnerships and maintain significant development and commercial rights.

    Press Releases

    • Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

      05-30-2023

    • Kura Oncology to Participate in Two Upcoming Investor Conferences

      05-23-2023

    • Kura Oncology Reports First Quarter 2023 Financial Results

      05-10-2023

    Events

    • Kura Oncology EHA Investor Event

      06-12-2023 at 8:00 AM EDT

    • TD Cowen’s 4th Annual Oncology Innovation Summit

      05-30-2023 at 1:30 PM EDT

    • JMP Securities Life Sciences Conference

      05-16-2023 at 11:00 AM EDT

    Presentations

    Kura Oncology - Corporate Presentation - May 2023
    Investor Event Presentation

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
    Footer Links - Investors
    • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top